drug · small molecule
patient view →lorecivivint
pre_registrationupdated 2mo agoby Biosplice Therapeutics Inc🔗 ChEMBL
community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 3 investigational indications.
targets
Dual specificity protein kinase CLK2Dual specificity tyrosine-phosphorylation-regulated kinase 1A
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that